120 related articles for article (PubMed ID: 35279875)
41. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
42. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.
Biason P; Hattinger CM; Innocenti F; Talamini R; Alberghini M; Scotlandi K; Zanusso C; Serra M; Toffoli G
Pharmacogenomics J; 2012 Dec; 12(6):476-83. PubMed ID: 21826087
[TBL] [Abstract][Full Text] [Related]
43. miR-21 predicts poor prognosis in patients with osteosarcoma.
Ren X; Shen Y; Zheng S; Liu J; Jiang X
Br J Biomed Sci; 2016 Oct; 73(4):158-162. PubMed ID: 27922432
[TBL] [Abstract][Full Text] [Related]
44. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.
Chen X; Bahrami A; Pappo A; Easton J; Dalton J; Hedlund E; Ellison D; Shurtleff S; Wu G; Wei L; Parker M; Rusch M; Nagahawatte P; Wu J; Mao S; Boggs K; Mulder H; Yergeau D; Lu C; Ding L; Edmonson M; Qu C; Wang J; Li Y; Navid F; Daw NC; Mardis ER; Wilson RK; Downing JR; Zhang J; Dyer MA;
Cell Rep; 2014 Apr; 7(1):104-12. PubMed ID: 24703847
[TBL] [Abstract][Full Text] [Related]
45. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.
Ma W; Zhang X; Chai J; Chen P; Ren P; Gong M
Tumour Biol; 2014 Dec; 35(12):12467-72. PubMed ID: 25185654
[TBL] [Abstract][Full Text] [Related]
46. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.
Buddingh EP; Kuijjer ML; Duim RA; Bürger H; Agelopoulos K; Myklebost O; Serra M; Mertens F; Hogendoorn PC; Lankester AC; Cleton-Jansen AM
Clin Cancer Res; 2011 Apr; 17(8):2110-9. PubMed ID: 21372215
[TBL] [Abstract][Full Text] [Related]
47. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic significance of S100A4 expression in osteosarcoma.
Cao CM; Yang FX; Wang PL; Yang QX; Sun XR
Eur Rev Med Pharmacol Sci; 2014; 18(6):833-9. PubMed ID: 24706307
[TBL] [Abstract][Full Text] [Related]
49. ERCC polymorphisms and prognosis of patients with osteosarcoma.
Li J; Liu S; Wang W; Zhang K; Liu Z; Zhang C; Chen S; Wu S
Tumour Biol; 2014 Oct; 35(10):10129-36. PubMed ID: 25023406
[TBL] [Abstract][Full Text] [Related]
50. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma.
Kubota D; Mukaihara K; Yoshida A; Tsuda H; Kawai A; Kondo T
J Proteomics; 2013 Oct; 91():393-404. PubMed ID: 23911960
[TBL] [Abstract][Full Text] [Related]
51. Outstanding prognostic value of novel ferroptosis-related genes in chemoresistance osteosarcoma patients.
Zhao J; Zhao Y; Ma X; Feng H; Jia L
Sci Rep; 2022 Mar; 12(1):5029. PubMed ID: 35322804
[TBL] [Abstract][Full Text] [Related]
52. Combined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas.
Zhang C; Yao C; Li H; Wang G; He X
Int J Mol Sci; 2014 Apr; 15(4):6544-55. PubMed ID: 24747591
[TBL] [Abstract][Full Text] [Related]
53. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy.
Zhao J; Dean DC; Hornicek FJ; Yu X; Duan Z
Cancer Lett; 2020 Apr; 474():158-167. PubMed ID: 31987920
[TBL] [Abstract][Full Text] [Related]
54. Personalized care of pediatric cancer patients.
Rabin K; Man TK; Lau CC
Nestle Nutr Workshop Ser Pediatr Program; 2008; 62():173-85; discussion 185-8. PubMed ID: 18626200
[TBL] [Abstract][Full Text] [Related]
55. P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.
Tang Y; Yang C; Guo Z; Fu Y; Yu X; Liu B; Zhou H; Wang J; Li W; Pang Q
Medicine (Baltimore); 2017 May; 96(19):e6714. PubMed ID: 28489748
[TBL] [Abstract][Full Text] [Related]
56. MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.
Liu W; Zhao X; Zhang YJ; Fang GW; Xue Y
J Int Med Res; 2018 Mar; 46(3):975-983. PubMed ID: 29115164
[TBL] [Abstract][Full Text] [Related]
57. PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.
Li L; Liang S; Wasylishen AR; Zhang Y; Yang X; Zhou B; Shan L; Han X; Mu T; Wang G; Xiong S
Oncotarget; 2016 Apr; 7(14):18021-35. PubMed ID: 26933804
[TBL] [Abstract][Full Text] [Related]
58. Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.
Li Y; Zhao C; Yu Z; Chen J; She X; Li P; Liu C; Zhang Y; Feng J; Fu H; Wang B; Kuang L; Li L; Lv G; Wu M
Oncotarget; 2016 Oct; 7(42):68585-68596. PubMed ID: 27612424
[TBL] [Abstract][Full Text] [Related]
59. High levels of long non-coding RNA DICER1-AS1 are associated with poor clinical prognosis in patients with osteosarcoma.
Hu XH; Dai J; Shang HL; Zhao ZX; Hao YD
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7640-7645. PubMed ID: 30536305
[TBL] [Abstract][Full Text] [Related]
60. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.
Liu S; Yi Z; Ling M; Shi J; Qiu Y; Yang S
Tumour Biol; 2014 Oct; 35(10):9897-904. PubMed ID: 24996541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
